Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.0%
    Check dated 2026-11-03T23:24:11.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide NIH notice about using “Super Intelligence” instead of “Artificial Intelligence” appears, and the site revision advances from v3.7.1 to v3.7.2.
    Difference
    0.4%
    Check dated 2026-10-20T22:59:38.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The site footer’s revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.0%
    Check dated 2026-10-06T23:09:59.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.6 to v3.7.0, indicating a new site UI release rather than changes to the study content.
    Difference
    0.0%
    Check dated 2026-09-15T23:24:22.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The history adds a new site revision v3.6.6 and removes the previous v3.6.5, indicating an updated release of the page framework.
    Difference
    0.0%
    Check dated 2026-09-01T20:04:48.000Z thumbnail image
  8. Check
    81 days ago
    Change Detected
    Summary
    Outcome Measures (Results), Contacts/Locations, and Study Status have been added, signaling a newer version of the record with expanded access to current results, contact points, and status. The update reflects an enhanced organization of core study information for easier review and coordination.
    Difference
    0.3%
    Check dated 2026-08-25T20:12:38.000Z thumbnail image

Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.